Neuroimaging in dementia;Neuro-imagerie des démences

Presse Medicale

Volumn 36, Issue 10 II, 2007, Pages 1453-1463

  Lehéricy, Stéphane ^a   Delmaire, Christine ^b   Galanaud, Damien ^c   Dormont, Didier ^c,d  

^a INSERM   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d Centre National de la Recherche Scientifique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DEGENERATIVE DISEASE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; FRONTOTEMPORAL DEMENTIA; HUMAN; MULTIINFARCT DEMENTIA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIODIAGNOSIS; SHORT SURVEY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TOPOGRAPHY; BRAIN; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSONISM; PATHOLOGY; RADIOGRAPHY; REVIEW; SCINTISCANNING; SPECTROSCOPY;

ALZHEIMER DISEASE; BRAIN; DEMENTIA; DEMENTIA, VASCULAR; DIAGNOSIS, DIFFERENTIAL; HUMANS; LEWY BODY DISEASE; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; SPECTRUM ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34848908006     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2007.04.029     Document Type: Short Survey

References (43)

1. Jagust W. Molecular neuroimaging in Alzheimer's disease. NeuroRx 1 (2004) 206-212
2. Walker Z., Costa D.C., Ince P., McKeith I.G., and Katona C.L. In-vivo demonstration of dopaminergic degeneration in dementia with Lewy bodies. Lancet 354 (1999) 646-647
3. Geser F., Wenning G.K., Poewe W., and McKeith I. How to diagnose dementia with Lewy bodies: state of the art. Mov Disord 20 Suppl 12 (2005) S11-S20
4. Coleman R.E. Positron emission tomography diagnosis of Alzheimer's disease. Neuroimaging Clin N Am 15 (2005) 837-846
5. Herholz K., Salmon E., Perani D., Baron J.C., Holthoff V., Frolich L., et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 17 (2002) 302-316
6. Small G.W., Ercoli L.M., Silverman D.H., Huang S.C., Komo S., Bookheimer S.Y., et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 97 (2000) 6037-6042
7. Kantarci K., and Jack Jr. C.R. Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clin N Am 13 (2003) 197-209
8. Bastos Leite A.J., Scheltens P., and Barkhof F. Pathological aging of the brain: an overview. Top Magn Reson Imaging 15 (2004) 369-389
9. Lehericy S., Marjanska M., Mesrob L., Sarazin M., and Kinkingnehun S. Magnetic resonance imaging of Alzheimer's disease. Eur Radiol 17 (2007) 347-362
10. Perry R.H., Irving D., Blessed G., Fairbairn A., and Perry E.K. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 95 (1990) 119-139
11. Barber R., Gholkar A., Scheltens P., Ballard C., McKeith I.G., and O'Brien J.T. Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology 52 (1999) 1153-1158
12. Neary D., Snowden J.S., Northen B., and Goulding P. Dementia of frontal lobe type. J Neurol Neurosurg Psychiatry 51 (1988) 353-361
13. Weintraub S., and Mesulam M.-M. Four neuropsychological profiles in dementia. In: Boller F., and Grafman J. (Eds). Handbook of Neuropsychology (1993), Elsevier 253-282 (Vol. 8)
14. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2 (2003) 229-237
15. Burton E.J., McKeith I.G., Burn D.J., Williams E.D., and O'Brien J.T. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 127 (2004) 791-800
16. Burn D.J., and Lees A.J. Progressive supranuclear palsy: where are we now?. Lancet Neurol 1 (2002) 359-369
17. Gilman S., Low P.A., Quinn N., Albanese A., Ben-Shlomo Y., Fowler C.J., et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 163 (1999) 94-98
18. Oba H., Yagishita A., Terada H., Barkovich A.J., Kutomi K., Yamauchi T., et al. New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology 64 (2005) 2050-2055
19. Brenneis C., Seppi K., Schocke M., Benke T., Wenning G.K., and Poewe W. Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 75 (2004) 246-249
20. O'Brien J.T., Erkinjuntti T., Reisberg B., Roman G., Sawada T., Pantoni L., et al. Vascular cognitive impairment. Lancet Neurol 2 (2003) 89-98
21. Hachinski V.C., Lassen N.A., and Marshall J. Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet 2 (1974) 207-210
22. Bhatia K.P., and Marsden C.D. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain 117 (1994) 859-876
23. Roman G.C., Erkinjuntti T., Wallin A., Pantoni L., and Chui H.C. Subcortical ischaemic vascular dementia. Lancet Neurol 1 (2002) 426-436
24. Hachinski V.C., Potter P., and Merskey H. Leuko-araiosis. Arch Neurol 44 (1987) 21-23
25. de Groot J.C., de Leeuw F.E., Oudkerk M., Hofman A., Jolles J., and Breteler M.M. Cerebral white matter lesions and subjective cognitive dysfunction: the Rotterdam Scan Study. Neurology 56 (2001) 1539-1545
26. Du A.T., Schuff N., Laakso M.P., Zhu X.P., Jagust W.J., Yaffe K., et al. Effects of subcortical ischemic vascular dementia and AD on entorhinal cortex and hippocampus. Neurology 58 (2002) 1635-1641
27. Chetelat G., and Baron J.C. Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. Neuroimage 3 18 (2004) 525-541
28. Kantarci K., and Jack Jr. C.R. Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clin N Am 13 (2003) 197-209
29. Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol 3 (2004) 519-527
30. Bobinski M., de Leon M.J., Convit A., De Santi S., Wegiel J., Tarshish C.Y., et al. MRI of entorhinal cortex in mild Alzheimer's disease. Lancet 353 (1999) 38-40
31. Jack Jr. C.R., Petersen R.C., Xu Y., O'Brien P.C., Smith G.E., Ivnik R.J., et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 55 (2000) 484-489
32. Fox N.C., Warrington E.K., and Rossor M.N. Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease. Lancet 353 (1999) 2125
33. Kantarci K., Petersen R.C., Boeve B.F., Knopman D.S., Tang-Wai D.F., O'Brien P.C., et al. 1H MR spectroscopy in common dementias. Neurology 63 (2004) 1393-1398
34. Waldman A.D., Rai G.S., McConnell J.R., Chaudry M., and Grant D. Clinical brain proton magnetic resonance spectroscopy for management of Alzheimer's and sub-cortical ischemic vascular dementia in older people. Arch Gerontol Geriatr 35 (2002) 137-142
35. Seppi K., Schocke M.F., Wenning G.K., and Poewe W. How to diagnose MSA early: the role of magnetic resonance imaging. J Neural Transm 112 (2005) 1625-1634
36. Le Bihan D., Mangin J.F., Poupon C., Clark C.A., Pappata S., Molko N., et al. Diffusion tensor imaging: concepts and applications. J Magn Reson Imaging 13 (2001) 534-546
37. Kantarci K., Petersen R.C., Boeve B.F., Knopman D.S., Weigand S.D., O'Brien P.C., et al. DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 64 (2005) 902-904
38. Krishnan S., Talley B.D., Slavin M.J., Doraiswamy P.M., and Petrella J.R. Current status of functional MR imaging, perfusion-weighted imaging, and diffusion-tensor imaging in Alzheimer's disease diagnosis and research. Neuroimaging Clin N Am 15 (2005) 853-868
39. Kalus P., Slotboom J., Gallinat J., Mahlberg R., Cattapan-Ludewig K., Wiest R., et al. Examining the gateway to the limbic system with diffusion tensor imaging: The perforant pathway in dementia. Neuroimage 30 (2006) 730-820
40. Jack C.R.Jr., Garwood M., Wengenack T.M., Borowski B., Curran G.L., Lin J., et al. In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn Reson Med 52 (2004) 1263-1271
41. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55 (2004) 306-319
42. Edison P., Archer H.A., Hinz R., Hammers A., Pavese N., Tai Y.F., et al. Amyloid, hypometabolism, and cognition in Alzheimer disease. An [11C]PIB and [18F]FDG PET study. Neurology 68 (2007) 501-508
43. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59 (2006) 512-519